Overview

Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

1. To study the symptomatic improvement in LUTS afforded by FLOMAX® capsules, 0.4 mg daily compared to placebo, in female patients with lower urinary tract symptoms (LUTS) with a significant component of voiding symptoms 2. To study the improvement afforded by FLOMAX® capsules versus placebo, in this patient population, in quality of life 3. To assess the safety and tolerability of FLOMAX® capsules, 0.4 mg compared to placebo, in women suffering from LUTS with a significant component of voiding symptoms

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Tamsulosin